ArticleBMC cancer2025
Single-cell and spatial transcriptomics reveal lactylation-associated tumor cell clusters and define a prognostic risk model in glioblastoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Lactate metabolism and protein lactylation in inflammatory and tumor microenvironments.Molecular biomedicine · 2026Review
- Leveraging single-cell and spatial omics for brain tumour insights to improve therapeutic strategies.Molecular brain · 2026Review
- Histone lactylation-mediated glycolysis-ferroptosis axis in neurological diseases.Frontiers in molecular neuroscience · 2026Review
- Multifaceted roles of S100A6 in neurological disorders: expression, interaction networks, and clinical implications.Frontiers in pharmacology · 2026Review
- Metabolic reprogramming and immune evasion interaction in the tumor microenvironment promote tumor progression.Frontiers in oncology · 2026Review
- Lactylation in cancer: mechanistic insights, tumor microenvironment, and therapeutic horizons.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma (GBM) is the most aggressive adult brain tumor, marked by intratumoral heterogeneity and therapy resistance. Metabolic reprogramming through histone lactylation has been linked to tumor progression and immune suppression. However, the spatial and single-cell landscape of lactylation in GBM and its prognostic significance remain poorly understood.
methodsWe employed a multi-omics approach integrating bulk RNA sequencing, single-cell RNA sequencing (scRNA-seq), and spatial transcriptomics to investigate lactylation-related signatures in GBM. Differential expression and pathway analyses were performed using GEO and TCGA datasets. Cell clustering, SCENIC transcriptional network inference, CellChat intercellular communication modeling, and pseudotime analysis were conducted. A prognostic risk model was constructed using LASSO-Cox regression based on lactylation-associated genes. Experimental validation was performed using western blotting, immunohistochemistry, and functional assays in GBM cell lines.
resultsLactylation-related genes were significantly upregulated in GBM and associated with poor prognosis and immunosuppressive tumor microenvironments. Single-cell analysis revealed high-lactylation malignant subpopulations enriched in hypoxic tumor cores, exhibiting metabolic reprogramming and enhanced immune evasion. Spatial transcriptomics confirmed the localization of S100A6-high-lactylation GBM cells in aggressive tumor regions. A nine-gene lactylation-based risk model stratified patients into high- and low-risk groups with significantly different survival outcomes (AUC: 0.77-0.87). Experimental knockdown of S100A6 reduced GBM cell proliferation, migration, and invasion.
conclusionsLactylation defines distinct tumor cell clusters in GBM that are spatially localized, metabolically reprogrammed, and immunosuppressive. The S100A6-associated lactylation signature serves as a robust prognostic biomarker and potential therapeutic target in GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.